Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemiaHagop M. Kantarjian, Jean‐Pierre J. Issa, Yasuhiro Oki et al.|Blood|2006Cited by 691
Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:Hagop M. Kantarjian, Elihu H. Estey, Susan O’Brien et al.|Cancer|2006Cited by 607
Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemiaHagop Kantarjian, Emil J. Freireich, Guillermo Garcia‐Manero et al.|Blood|2010Cited by 399
DNA Methylation Predicts Survival and Response to Therapy in Patients With Myelodysplastic SyndromesLanlan Shen, Jean‐Pierre J. Issa, Hagop M. Kantarjian et al.|Journal of Clinical Oncology|2009Cited by 359
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitorsJörge E. Cortes, Dan Jones, Elias Jabbour et al.|Blood|2007Cited by 298